Table 2 Association of insulin resistance index with new onset hypertension

TyG index

1.804 (1.620–2.008)

< 0.001

1.135 (0.999–1.290)

0.052

1.083 (0.951–1.235)

0.22

TG/HDL-C

1.097 (1.076–1.118)

< 0.001

1.029 (1.002–1.056)

0.03

1.023 (0.995–1.052)

0.10

METS-IR

5.135 (3.893–6.774)

< 0.001

1.594 (1.111–2.286)

0.01

1.389 (0.958–2.014)

0.08

ZJU index

1.012 (1.010–1.015)

< 0.001

1.003 (0.999–1.007)

0.10

1.003 (0.999–1.008)

0.09

Incidence of stage I hypertension

TyG index

1.716 (1.566–1.981)

< 0.001

1.102 (0.958–1.268)

0.17

1.049 (0.909–1.210)

0.51

TG/HDL-C

1.115 (1.088–1.141)

< 0.001

1.037 (1.004–1.071)

0.02

1.028 (0.995–1.063)

0.10

METS-IR

5.146 (3.783–6.999)

< 0.001

1.611 (1.085–2.392)

0.01

1.392 (0.927–2.090)

0.11

ZJU index

1.012 (1.009–1.014)

< 0.001

1.002 (0.997–1.007)

0.50

1.001 (0.996–1.006)

0.59

Incidence of stage II hypertension

TyG index

2.907 (2.254–3.749)

< 0.001

1.527 (1.111–2.101)

0.009

1.409 (1.024–1.939)

0.03

TG/HDL-C

1.141 (1.101–1.183)

< 0.001

1.057 (1.002–1.115)

0.04

1.044 (0.987–1.105)

0.13

METS-IR

15 733 (8.195–30.205)

< 0.001

2.998 (1.203–7.473)

0.01

2.317 (0.904–5.938)

0.08

ZJU index

1.018 (1.014–1.023)

< 0.001

1.010 (1.004–1.017)

0.002

1.010 (1.004–1.017)

0.002